With Seizure in Florida, FDA Targets Kratom As Unsafe For Any Use
Executive Summary
Kratom industry says complaint filed in Florida federal court shows FDA’s switching reasons to stop all sales of the ingredient in the US.
You may also be interested in...
US Kratom Warnings Note Opioid Withdrawal Claims, Omit Unlawful Ingredient Reference
FDA and FTC joint warnings to four kratom firms as well as an essential oil marketer explain they're acting under Department of Health and Human Services’ declaration of a public health emergency involving the opioid crisis.
FDA’s Proposed IND Study For ‘Abuse Potential’ Could Close US Kratom Supplement Market
RFP states FDA "previously warned consumers about the use of Kratom (Mitragyna speciosa)” and although botanical’s “use is prevalent, to date, clinical evaluations of abuse potential have not been performed.”
Another Notice For Comments On Kratom: Cue Second Wave Of Support For Botanical In US?
FDA states in Federal Register notice that WHO has requested information on whether kratom – mitragynine, 7-hydroxymitragynine – should be added to the United Nations’ schedule of controlled substances.